The initial public offer (IPO) of Glenmark Life Sciences was subscribed 45.08 times on Thursday, the concluding day of the issue.
The institutional investor portion was subscribed 37.3 times, the wealthy investor portion was subscribed 125.6 times, and the retail portion was subscribed 15 times.
Meanwhile, the IPO of Rolex Rings was subscribed 9.3 times a day before its close. The institutional portion was subscribed 23 per cent, the wealthy investor portion by 5.8 times and the retail investor portion by 16 times.
Glenmark Life Sciences, a developer and manufacturer of active pharmaceutical ingredients (APIs), had priced its IPO between